- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02822989
Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain
September 8, 2020 updated by: Cynthia Aranow, MD, Northwell Health
Using the Cholinergic Anit-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune, inflammatory disease and musculoskeletal pain is one of the most common symptoms.
This study will investigate whether transcutaneous stimulation of the vagus nerve will decrease lupus musculoskeletal pain.
This study will additionally investigate the biologic effects of vagus nerve stimulation on inflammation.
It will be the first clinical study using one of the body's own pathways of modulating the immune system and inflammatory response, the cholinergic anti-inflammatory pathway, in SLE.
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
18
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Manhasset, New York, United States, 11030
- Feinstein Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥18 years,
- SLE (defined by the ACR or SLICC criteria),
- Musculoskeletal pain ≥ 4 on a non-anchored VAS 10 cm scale
- BILAG C on Musculoskeletal Domain of the BILAG 2004
- If on corticosteroids, the dose must be stable and ≤ 10mg/day (prednisone or equivalent) for at least 28 days before baseline,
- If on background immunosuppressive treatment the dose must be stable for at least 28 days before baseline
- Able and willing to give written informed consent and comply with the requirements of the study protocol.
Exclusion Criteria:
- Treatment with rituximab within one year of baseline (subjects with previous treatment with rituximab can enter study only with documentation of B cell repletion),
- Treatment with cyclophosphamide within 2 months of baseline,
- Expectation to increase steroids and/or immunosuppressive treatment,
- Anti-phospholipid syndrome,
- Fibromyalgia (fibromyalgia will be defined as a score > 13 on the Fibromyalgia Symptom Scale (FSS).
- Treatment with an anti-cholinergic medication, including over the counter medications,
- Implantable electronic devices such as pacemakers, defibrillators, hearing aids, cochlear implants or deep brain stimulators.
- Current tobacco or nicotine user,
- Joint replacement within 60 days prior to study enrollment or planned within the course of the study,
- Any planned surgical procedure requiring general anesthesia within the course of the study,
- Intra-articular cortisone injections within 28 days of the start of study,
- Chronic inflammatory disorders apart from SLE affecting the joints,
- Investigational drug and/or treatment during the 28 days or seven half-lives of the investigational drug prior to the start of study drug dosing (Day 0), whichever is the greater length of time,
- Active infection including hepatitis B or hepatitis C at baseline,
- Any condition which, in the opinion of the investigator, would jeopardize the subject's safety following exposure to a study intervention,
- Pregnancy or lactation,
- Comorbid disease that may require administration of corticosteroid use,
- Inability to comply with study and follow-up procedures.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Vagus Nerve Stimulation
Subjects randomized to this arm will receive transcutaneous vagus nerve stimulation for 5 minutes on 4 consecutive days.
|
Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days.
The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation.
The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal.
Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch.
|
Sham Comparator: Sham Vagus Nerve Stimulation
Subjects randomized to this arm will receive sham stimulation for 5 minutes for 4 consecutive days.
|
Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days.
Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Musculoskeletal pain.
Time Frame: 5 days
|
Patients rate their musculoskeletal pain by making a mark on a 10cm anchored Visual Analog Scale where 0=no musculoskeletal pain and 10 =worst possible musculoskeletal pain.
|
5 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SLE Disease activity
Time Frame: 5 days
|
SLE disease activity will be assessed using the SLEDAI, a validated disease activity instrument for SLE.
|
5 days
|
Fatigue
Time Frame: 5 days
|
Fatigue will be measured using the FACET F questionnaire which will be completed by each subject.
|
5 days
|
Fatigue
Time Frame: 12 days
|
Fatigue will be measured using the FACET F questionnaire which will be completed by each subject.
|
12 days
|
Tender and swollen joint counts
Time Frame: 5 days
|
The number of tender and swollen joints of the subject will be assessed by the investigator who will examine 68 potential tender joints and 66 potential swollen joints.
|
5 days
|
Tender and swollen joint counts
Time Frame: 12 days
|
The number of tender and swollen joints of the subject will be assessed by the investigator who will examine 68 potential tender joints and 66 potential swollen joints.
|
12 days
|
SLE cutaneous activity
Time Frame: 5 days
|
Cutaneous activity will be assessed using the CLASI, a validated index for SLE skin disease.
|
5 days
|
SLE cutaneous activity
Time Frame: 12 days
|
Cutaneous activity will be assessed using the CLASI, a validated index for SLE skin disease.
|
12 days
|
Musculoskeletal Pain
Time Frame: 12 days
|
Patients rate their musculoskeletal pain by making a mark on a 10cm anchored Visual Analog Scale where 0=no musculoskeletal pain and 10 =worst possible musculoskeletal pain.
|
12 days
|
Percentage of subjects with treatment emergent adverse events.
Time Frame: 12 days
|
The percentage of participants with treatment emergent adverse events will be assessed using the NCI-CTAEversion4.
|
12 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TNF, HMGB1, IL-6, Il1B, IFNα and IL10 levels
Time Frame: 5 days
|
Levels of inflammatory cytokines (ie TNF, HMGB1, IL-6, Il1B, IFNα and IL10) will be measured in patients sera.
|
5 days
|
TNF, HMGB1, IL-6, Il1B, IFNα and IL10 levels
Time Frame: 12 days
|
Levels of inflammatory cytokines (ie TNF, HMGB1, IL-6, Il1B, IFNα and IL10) will be measured in patients sera.
|
12 days
|
Lipopolysaccharide stimulated levels of TNF, HMGB1, IL-6, Il1B, IFNα and IL10 in whole blood.
Time Frame: 5 days
|
Whole blood will be taken from patients and stimulated by lipopolysaccharide.
Levels of TNF, HMGB1, IL-6, Il1B, IFNα and IL10 that are produced by the cells in the whole blood will be measured.
|
5 days
|
Lipopolysaccharide stimulated levels of TNF, IL-6, Il1B, IFNα and IL10 in whole blood.
Time Frame: 12 days
|
Whole blood will be taken from patients and stimulated by lipopolysaccharide.
Levels of TNF, HMGB1, IL-6, Il1B, IFNα and IL10 that are produced by the cells in the whole blood will be measured.
|
12 days
|
Gardiquimod stimulated levels of TNF, IL-6, Il1B, IFNα and IL10 in whole blood.
Time Frame: 5 days
|
Whole blood will be taken from patients and stimulated by gardiquimod.. Levels of TNF, HMGB1, IL-6, Il1B, IFNα and IL10 that are produced by the cells in the whole blood will be measured.
|
5 days
|
Gardiquimod stimulated levels of TNF, IL-6, Il1B, IFNα and IL10 in whole blood.
Time Frame: 12 days
|
Whole blood will be taken from patients and stimulated by gardiquimod.. Levels of TNF, HMGB1, IL-6, Il1B, IFNα and IL10 that are produced by the cells in the whole blood will be measured.
|
12 days
|
CpG stimulated levels of TNF, IL-6, Il1B, IFNα and IL10 in whole blood.
Time Frame: 5 days
|
Whole blood will be taken from patients and stimulated by CpG.
Levels of TNF, HMGB1, IL-6, Il1B, IFNα and IL10 that are produced by the cells in the whole blood will be measured.
|
5 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Cynthia Aranow, M.D., Northwell Health
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2017
Primary Completion (Actual)
April 30, 2018
Study Completion (Anticipated)
November 1, 2020
Study Registration Dates
First Submitted
May 26, 2016
First Submitted That Met QC Criteria
July 5, 2016
First Posted (Estimate)
July 6, 2016
Study Record Updates
Last Update Posted (Actual)
September 9, 2020
Last Update Submitted That Met QC Criteria
September 8, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-0171
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Musculoskeletal Pain
-
Sykehuset i Vestfold HFActive, not recruitingBack Pain | Musculoskeletal Pain | Chronic Pain | Musculoskeletal Diseases or Conditions | Pain, Chronic | Musculoskeletal Disorder | Musculoskeletal Neck PainNorway
-
University of Missouri, Kansas CityTerminatedOrthopaedic Related Pain (Musculoskeletal Pain)United States
-
Uppsala UniversityDalarna County Council, Sweden; Center for Clinical Research Dalarna, Sweden; REHSAM, SwedenTerminatedMusculoskeletal Neck Pain | Musculoskeletal Shoulder PainSweden
-
NORCE Norwegian Research Centre ASHelse Sor-Ost; Sykehuset i Vestfold HFCompletedNeck Pain Musculoskeletal | Back Pain Lower BackNorway
-
Stanford UniversityNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingPain | Joint Pain | Pain, Chronic | Chronic Musculoskeletal PainUnited States
-
University of North Carolina, Chapel HillYale University; Duke University; National Institute on Aging (NIA); Indiana University and other collaboratorsCompletedChronic Pain | Acute Musculoskeletal PainUnited States
-
Massachusetts General HospitalOrthopaedic Trauma AssociationCompleted
-
Wayne State UniversityUniversity of MichiganCompleted
-
Wayne State UniversityBlue Cross Blue Shield of Michigan FoundationCompleted
-
Wayne State UniversityUniversity of Southern CaliforniaCompleted
Clinical Trials on Vagus nerve stimulation
-
Peking University People's HospitalEnrolling by invitationChemotherapy-induced Peripheral Neuropathy | CIPNChina
-
University Hospital, GhentResearch Foundation FlandersCompletedEpilepsyBelgium, United States
-
Baylor Research InstituteUniversity of Texas Southwestern Medical Center; Wings for Life; The University... and other collaboratorsRecruitingSpinal Cord Injuries | Upper Extremity ParesisUnited States
-
Northwell HealthCompletedStroke | Hemiparesis | Cerebrovascular Accident (CVA)United States
-
Baylor Research InstituteNational Institute of Neurological Disorders and Stroke (NINDS); University... and other collaboratorsRecruitingStroke | Ischemic Stroke | Hemorrhagic Stroke | Upper Extremity Paresis | Chronic StrokeUnited States
-
Xidian UniversityUnknown
-
Xuzhou Central HospitalThe Affiliated Hospital of Xuzhou Medical University; The First People's Hospital...Not yet recruitingPostoperative Delirium | Postoperative Cognitive Dysfunction | Chronic Post Operative PainChina
-
University Hospital, GrenobleRecruiting
-
Sahlgrenska University Hospital, SwedenRecruitingBorderline Personality DisorderSweden
-
Massachusetts General HospitalBrain & Behavior Research FoundationCompletedMajor Depressive DisorderUnited States